ABBV · Health Care pick
AbbVie
Next earnings
- Date
- Oct 30, 2026
- Timing
- Before open
Why it was picked
Large-cap drugmaker; reports Oct 30 before the open (company-announced).
Latest report
Reported Jul 31, 2026
Q2 GAAP results include acquired IPR&D and milestones expense; AbbVie said Q3 will include $216 million of it.
Source: SEC EDGAR (opens in new tab)
Recap
ABBV Q2 2026: revenue up 10.2% year over year to $16.99 billion, net income up 285.2%.
Diluted EPS $2.03 vs. $0.52 (GAAP). AbbVie flagged acquired IPR&D and milestones expense in both periods.